BioNexus Gene Lab Corp Common stock (NASDAQ:BGLC) — Market Cap & Net Worth
Market Cap & Net Worth: BioNexus Gene Lab Corp Common stock (BGLC)
BioNexus Gene Lab Corp Common stock (NASDAQ:BGLC) has a market capitalization of $4.91 Million ($4.91 Million) as of May 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28393 globally and #5588 in its home market, demonstrating a -6.78% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioNexus Gene Lab Corp Common stock's stock price $2.08 by its total outstanding shares 2363836 (2.36 Million). Analyse BGLC cash generation efficiency to see how efficiently the company converts income to cash.
BioNexus Gene Lab Corp Common stock Market Cap History: 2020 to 2026
BioNexus Gene Lab Corp Common stock's market capitalization history from 2020 to 2026. Data shows change from $65.24 Million to $4.91 Million (-14.20% CAGR).
Index Memberships
BioNexus Gene Lab Corp Common stock is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2686 of 3165 |
Weight: BioNexus Gene Lab Corp Common stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
BioNexus Gene Lab Corp Common stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioNexus Gene Lab Corp Common stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.07x
BioNexus Gene Lab Corp Common stock's market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $65.24 Million | $11.39 Million | $1.09 Million | 5.73x | 59.63x |
| 2021 | $60.42 Million | $13.36 Million | $751.57K | 4.52x | 80.39x |
| 2022 | $26.95 Million | $10.93 Million | -$355.97K | 2.47x | N/A |
| 2023 | $1.25 Million | $9.77 Million | -$2.63 Million | 0.13x | N/A |
| 2024 | $661.16K | $9.51 Million | -$1.60 Million | 0.07x | N/A |
Competitor Companies of BGLC by Market Capitalization
Companies near BioNexus Gene Lab Corp Common stock in the global market cap rankings as of May 3, 2026.
Key companies related to BioNexus Gene Lab Corp Common stock by market ranking:
- Linde plc Ordinary Shares (NASDAQ:LIN): Ranked #91 globally with a market cap of $210.18 Billion USD.
- Air Liquide SA (PA:AI): Ranked #222 globally with a market cap of $108.00 Billion USD ( €92.38 Billion EUR).
- AIR LIQUIDE ADR 1/5/EO 11 (F:AILA): Ranked #232 globally with a market cap of $103.86 Billion USD ( €88.84 Billion EUR).
- Sherwin-Williams Co (NYSE:SHW): Ranked #334 globally with a market cap of $78.83 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #91 | Linde plc Ordinary Shares | NASDAQ:LIN | $210.18 Billion | $507.92 |
| #222 | Air Liquide SA | PA:AI | $108.00 Billion | €183.08 |
| #232 | AIR LIQUIDE ADR 1/5/EO 11 | F:AILA | $103.86 Billion | €36.60 |
| #334 | Sherwin-Williams Co | NYSE:SHW | $78.83 Billion | $318.00 |
BioNexus Gene Lab Corp Common stock Historical Marketcap From 2020 to 2026
Between 2020 and today, BioNexus Gene Lab Corp Common stock's market cap moved from $65.24 Million to $ 4.91 Million, with a yearly change of -14.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.91 Million | -47.37% |
| 2025 | $9.34 Million | +1312.23% |
| 2024 | $661.16K | -47.23% |
| 2023 | $1.25 Million | -95.35% |
| 2022 | $26.95 Million | -55.40% |
| 2021 | $60.42 Million | -7.39% |
| 2020 | $65.24 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of BioNexus Gene Lab Corp Common stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.91 Million USD |
| MoneyControl | $4.91 Million USD |
| MarketWatch | $4.91 Million USD |
| marketcap.company | $4.91 Million USD |
| Reuters | $4.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; a… Read more